Table 2.
DNA damage repair-related miRNAs and their effects on the susceptibility of cancer cells to anti-cancer treatments.
| MiRNAs | Target Gene(s) | Cancer Type | Effect of MiRNAs | Ref. |
|---|---|---|---|---|
| miR-7-5p | PARP1 | Lung cancer | Over-expression of miR-7-5p increases the overall cytotoxicity of doxorubicin | [55] |
| miR-30-5p | FANCF, REV1 | Breast cancer | Over-expression of miR-30-5p raises the anti-cancer effect of doxorubicin | [56] |
| miR-138-5p | ERCC1, ERCC4 | Gastric cancer | Knockdown of miR-138-5p lowers the efficacy of cisplatin, thus enhancing cisplatin resistance | [58] |
| miR-182-5p | BRCA1, RAD51 | Breast cancer, Acute Myelogenous Leukemia | Silencing of miR-182-5p results in resistance to PARP1 inhibitors and CNDAC | [63,64] |
| miR-205-5p | PRKCE, ZEB1 | Prostate cancer | Reconstitution of miR-205-5p escalates the efficiency of radiotherapy | [68] |
| miR-211-5p | POLH, TDP1, ATRX, MRPS11, ERCC6L2 | Ovarian cancer | Elevated miR-211-5p levels improve the overall cytotoxicity of carboplatin | [69] |
| miR-488-3p | EIF3A | Lung cancer | Elevated miR-488-3p levels impede cisplatin-mediated induction of cell death and growth inhibition | [73] |
| miR-493-5p | CHD4 | Ovarian cancer | Down-regulation of miR-493-5p levels leads to enhanced responsiveness to cisplatin and olaparib | [75] |
| miR-520g-3p, miR-520h | APEX1 | Multiple myeloma | Over-expression of both miR-520g-3p and miR-520h hampers the growth of bortezomib resistant multiple myeloma cells | [69] |
| miR-4429 | RAD51 | Cervical cancer | Over-expression of miR-4429 enhances radiosensitivity | [65] |